US medical devices industry sees a drop of 21.7% in deal activity in April 2020

20 May 2020 (Last Updated May 20th, 2020 15:54)

US medical devices industry sees a drop of 21.7% in deal activity in April 2020

The US medical devices industry saw a drop of 21.7% in overall deal activity during April 2020, when compared with the last 12-month average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 65 deals worth $459.95m were announced in April 2020, compared to the 12-month average of 83 deals.

Venture financing was the leading category in the month in terms of volume with 47 deals which accounted for 72.3% of all deals.

In second place was M&A with 13 deals, followed by private equity with five transactions, respectively accounting for 20% and 7.7% of overall deal activity in the country’s medical devices industry during the month.

In terms of value of deals, venture financing was the leading deal category in the US medical devices industry with total deals worth $418.2m, followed by private equity deals totalled $41.74m.

US medical devices industry deals in April 2020: Top deals

The top five medical devices industry deals accounted for 43.7% of the overall value during April 2020.

The combined value of the top five medical devices deals stood at $201.2m, against the overall value of $459.95m recorded for the month.

The top five medical devices industry deals of April 2020 tracked by GlobalData were:

1) Cedars-Sinai Medical Center, John Doerr and Pitango Venture Capital’s $70m venture financing of Click Diagnostics

2) The $50m venture financing of Dascena by Euclidean Capital, Frazier Healthcare Partners and Longitude Capital Management Co

3) Clinton Capital Partners, Perennial Value Management, ROTH Capital Partners and Vickers Venture Partners’ $34m venture financing of Lumitron Technologies

4) The $25m venture financing of AtaCor Medical by aMoon Partners, Broadview Ventures, Catalyst Health Ventures, Hatteras Venture Partners and Longview Ventures

5) Casdin Capital and Sofinnova Crossover I Fund’s private equity deal with MaxCyte for $22.2m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.